Automated Urine Microscope Verified for Regional Laboratories
By LabMedica International staff writers Posted on 03 Feb 2021 |

Image: The UriSed 3 PRO is a professional automated urine sediment analyzer with a revolutionary new optical system combining bright-field and phase contrast microscopy (Photo courtesy of 77 Elektronika)
Automated Urine Microscopy examines a sample of urine under a microscope. It can check cells from the urinary tract, blood cells, crystals, bacteria, parasites, and cells from tumors. This test is often used to confirm the findings of other tests or add information to a diagnosis.
Automation of urine particle counting has become a clinical standard in medium-sized and large laboratories by means of flow cytometry or several types of image analyzers. Reliable implementation of those instruments requires utilization of reference procedures in their verification.
Clinical Chemists and Microbiologists from Helsinki University Hospital (Helsinki, Finland) carried out the primary verification with 463 urine specimens, and against urine culture on chromogenic agar plates with 396 parallel specimens. Nine secondary instruments were compared pairwise with the primary instrument. Both mid-stream collections (generally 90% of all specimens) and catheterized specimens were taken into the study, based on particle findings.
Specimens were chosen from routine analysis by UF-1000i instrument (Sysmex, Kobe, Japan) for verification of the primary (“Gold”) UriSed 3 PRO instrument (77 Elektronika, Budapest, Hungary) against reference visual microscopy during a 6-week period in September - October 2018. Comparisons to urine culture results were available for 396 parallel samples which were cultured by using automated inoculation with 1 µL loop (WASP automated microbiology instrument, COPAN Wasp, Brescia, Italy) on chromogenic agar plates (CHROMagar Orientation medium, CHROMagar, Paris, France) following incubation at 35 °C for 18 hours.
The scientists reported that relative imprecisions compared to Poisson distribution, R(CV), were estimated to be 1.0 for white blood cell (WBC) and 1.5 for red blood cell (RBC) counts, respectively. Spearman’s correlations against visual microscopy were rS = 0.94 for WBC, rS = 0.87 for RBC, and rS = 0.82 for squamous epithelial cell (SEC) counts. Agreement with visual microscopy (Cohen’s weighted kappa) was 0.94 for WBC, 0.89 for RBC, 0.88 for SEC, 0.59 for combined casts, and 0.49 for non-squamous epithelial cells (NEC). Bacteria were detected with a sensitivity of 90% and specificity of 39 against culture at 107 colony forming bacteria/L (CFB/L = 104 CFU/mL). Created flagging limits allowed automated reporting for 70-75 % of patient results.
The authors were able to install 10 UriSed 3 PRO instruments in a regional laboratory environment at HUSLAB, providing about 160,000 automated particle counts annually at 24/7 basis, thus satisfying both routine testing and emergency analysis of clinical samples. Analytical performance fulfilled the analytical performance specifications and expectations obtained from preliminary testing. The study was published on January 26, 2021 in the journal Clinica Chimica Acta.
Related Links:
Helsinki University Hospital
Sysmex
77 Elektronika
COPAN Wasp
CHROMagar
Automation of urine particle counting has become a clinical standard in medium-sized and large laboratories by means of flow cytometry or several types of image analyzers. Reliable implementation of those instruments requires utilization of reference procedures in their verification.
Clinical Chemists and Microbiologists from Helsinki University Hospital (Helsinki, Finland) carried out the primary verification with 463 urine specimens, and against urine culture on chromogenic agar plates with 396 parallel specimens. Nine secondary instruments were compared pairwise with the primary instrument. Both mid-stream collections (generally 90% of all specimens) and catheterized specimens were taken into the study, based on particle findings.
Specimens were chosen from routine analysis by UF-1000i instrument (Sysmex, Kobe, Japan) for verification of the primary (“Gold”) UriSed 3 PRO instrument (77 Elektronika, Budapest, Hungary) against reference visual microscopy during a 6-week period in September - October 2018. Comparisons to urine culture results were available for 396 parallel samples which were cultured by using automated inoculation with 1 µL loop (WASP automated microbiology instrument, COPAN Wasp, Brescia, Italy) on chromogenic agar plates (CHROMagar Orientation medium, CHROMagar, Paris, France) following incubation at 35 °C for 18 hours.
The scientists reported that relative imprecisions compared to Poisson distribution, R(CV), were estimated to be 1.0 for white blood cell (WBC) and 1.5 for red blood cell (RBC) counts, respectively. Spearman’s correlations against visual microscopy were rS = 0.94 for WBC, rS = 0.87 for RBC, and rS = 0.82 for squamous epithelial cell (SEC) counts. Agreement with visual microscopy (Cohen’s weighted kappa) was 0.94 for WBC, 0.89 for RBC, 0.88 for SEC, 0.59 for combined casts, and 0.49 for non-squamous epithelial cells (NEC). Bacteria were detected with a sensitivity of 90% and specificity of 39 against culture at 107 colony forming bacteria/L (CFB/L = 104 CFU/mL). Created flagging limits allowed automated reporting for 70-75 % of patient results.
The authors were able to install 10 UriSed 3 PRO instruments in a regional laboratory environment at HUSLAB, providing about 160,000 automated particle counts annually at 24/7 basis, thus satisfying both routine testing and emergency analysis of clinical samples. Analytical performance fulfilled the analytical performance specifications and expectations obtained from preliminary testing. The study was published on January 26, 2021 in the journal Clinica Chimica Acta.
Related Links:
Helsinki University Hospital
Sysmex
77 Elektronika
COPAN Wasp
CHROMagar
Latest Clinical Chem. News
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
A tumor marker is a substance found in the body that may signal the presence of cancer. These substances, which can include proteins, genes, molecules, or other biological compounds, are either produced... Read more
Urine Test Diagnoses Early-Stage Prostate Cancer
Prostate cancer is one of the leading causes of death among men worldwide. A major challenge in diagnosing the disease is the absence of reliable biomarkers that can detect early-stage tumors.... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more